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12 Abstract Endometrial cancer (EC) is the most common
13 gynecologic malignancy of the female genital tract and the
14 fourth most common neoplasia in women. In EC, myo-
15 metrial invasion is considered one of the most important
16 prognostic factors. For this process to occur, epithelial
17 tumor cells need to undergo an epithelial to mesenchymal
18 transition (EMT), either transiently or stably, and to dif-
19 fering degrees. This process has been extensively described
20 in other types of cancer but has been poorly studied in EC.
21 In this review, several features of EMT and the main
22 molecular pathways responsible for triggering this process
23 are investigated in relation to EC. The most common
24 hallmarks of EMT have been found in EC, either at the
25level of E-cadherin loss or at the induction of its repressors,
26as well as other molecular alterations consistent with the
27mesenchymal phenotype-like L1CAM and BMI-1 up-reg-
28ulation. Pathways including progesterone receptor, TGFb,




33Endometrial cancer (EC) is made up of a biologically and
34histologically diverse group of neoplasms characterized by
35their distinct pathogeneses. These differential characteristics
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36 have been classified into a dualistic model, first proposed
37 by Bokhman [1]. Nowadays, this model is being chal-
38 lenged, since tumors seen in daily practice occasionally
39 show overlapping or combined morphologic and molecular
40 characteristics between both types, in addition to ambigu-
41 ous features [2]. Nevertheless, we still follow this classi-
42 fication as it is currently used in the clinical practice. Type
43 I, or estrogen-dependent endometrioid ECs, represent the
44 most common subtype. This type usually develops in peri-
45 and early postmenopausal women. It is an estrogen-asso-
46 ciated lesion often seen in conjunction with endometrial
47 hyperplasia. The histological subtypes that correspond to
48 endometrioid adenocarcinoma and its variants, as well as
49 mucinous adenocarcinoma, are allocated to this group.
50 Type II, or non-endometrioid ECs, tend to affect older,
51 postmenopausal women and are a non-estrogen-associated
52 lesion. These cancers are not preceded by endometrial
53 hyperplasia, though they can occasionally arise in endo-
54 metrial polyps or from precancerous lesions, endometrial
55 intraepithelial carcinoma, or in the vicinity of atrophic
56 endometrium [3]. The most virulent histologic subtypes,
57 such as papillary serous, clear cell carcinomas, and carci-
58 nosarcomas are to be found in this group [4]. The clini-
59 copathological differences between the two types are
60 paralleled by specific genetic alterations, with type I
61 showing microsatellite instability and mutations in PTEN,
62 PIK3CA, K-RAS, and CTNNB1 (beta-catenin) and type II
63 exhibiting TP53 mutations and chromosomal instability
64 [5].
65 Epidemiologically, EC is ranked as the most common
66 gynecologic malignancy of the female genital tract and the
67 fourth most common neoplasia in women after breast,
68 colorectal and lung cancer. Recent data from the US esti-
69 mates that 47,130 new cases of EC will be diagnosed in
70 2012, but only 8,010 deaths are expected [6]. According to
71 these statistics, EC is considered to be a good prognosis
72 cancer, since it is usually detected in its initial stages by the
73 presentation of disease-related symptoms. In its early
74 stages, EC is confined to the endometrium and can be
75 treated by hysterectomy with or without adjuvant treatment
76 resulting in survival rates around 96 % at 5 years. How-
77 ever, 30 % of all EC cases are still diagnosed at regional or
78 distant stages, and are related to lower survival rates, 67
79 and 16 %, respectively. When comparing the epidemiol-
80 ogic data of both EC types, type I lesions are generally
81 diagnosed at an earlier stage and possess a more favorable
82 prognosis than those of type II. Generally, type II are more
83 aggressive tumors that are commonly diagnosed in
84 advanced stages and often recur, despite aggressive
85 treatment [7].
86 In order to tackle the causes of mortality associated with
87 EC, it is necessary to understand how this cancer dissem-
88 inates. EC spreads by direct extension through the
89myometrium, in an exfoliation of cells that are shed
90through the fallopian tubes, lymphatic dissemination, and/
91or hematogenous dissemination [8]. The most common
92route of spread is the direct extension of a tumor to the
93myometrium. In this review, we will focus on the mecha-
94nisms that initiate this local invasion, as this invasion is
95considered one of the most important prognostic factors for
96type I and type II ECs, usually correlating with lymphatic
97spread, risk of recurrence, and overall survival rate. In the
98multistep process that characterizes myometrial invasion,
99the initial events are delineated by the dissociation of
100tumor cells from the epithelial layer of the endometrial
101glands and the penetration through the basement membrane
102into the adjacent connective tissue, i.e., the myometrium
103[7]. This process is similar in other types of cancer, and
104many authors [8, 9] have pointed out that for this process to
105occur, epithelial tumor cells need to undergo an epithelial
106to mesenchymal (EMT) transition, either transiently or
107stably, and to differing degrees.
108Epithelial to mesenchymal transition (EMT)
109EMT is a well-described process whereby epithelial cells
110lose their polarity and cell–cell contacts, undergoing a
111dramatic remodeling of the cytoskeleton and acquiring a
112migratory phenotype, which activates a mesenchymal-like
113gene expression program. The epithelial cells form a sheet
114or layer of cells that are tightly connected laterally by
115specialized junction structures, including adherens junc-
116tions, desmosomes, hemidesmosomes, tight junctions and
117gap junctions. Among these, adherens junctions play a
118particularly important role in assembling and constructing
119lateral epithelial cell–cell adhesions. The epithelial cells
120also establish an aligned, apical–basal polarity through
121their association with a lamina layer at their basal surface,
122which ensures that the cells are only able to migrate lat-
123erally, maintaining their position within the epithelium
124[10]. Upon receiving specific signals, EMT occurs. Mes-
125enchymal cells are defined by three major characteristics in
126their cellular phenotype and their behavior (Fig. 1): (1) a
127loss of strong epithelial adhesive cell–cell contacts and the
128acquisition of a dispersed, spindle-shaped morphology with
129migratory protrusions, (2) changes in the differentiation
130markers from cell–cell junction proteins, i.e., E-cadherin
131and cytokeratin intermediate filaments (specific to epithe-
132lial cells) to vimentin filaments and fibronectin, and (3) an
133increased motility for invasion through the extracellular
134matrices. All three changes are not necessarily observable
135during an EMT; however, the single cell acquisition of the
136ability to migrate and invade the extracellular matrices is
137considered to be a functional hallmark of EMT. Hence,
138mesenchymal cells are able to detach, penetrate through the
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139 basement membrane and infiltrate surrounding tissues to
140 then metastasize at secondary sites [11, 12]. To reach
141 successful dissemination, EMT must be triggered in epi-
142 thelial cells through an appropriate signaling pathway.
143 Cancer cells must also develop complex interactions to
144 integrate stimuli from their surrounding microenviron-
145 ments [13, 14].
146 Several transcription factors have emerged in recent
147 years that trigger the down-regulation of E-cadherin and,
148 consequently, produce EMT in different types of cancer.
149 These transcription factors include the transforming growth
150 factor-b (TGFb), epidermal growth factor (EGF), insulin
151 growth factor 1 (IGF-1), interleukin, vascular endothelial
152 growth factor (VEGF), platelet-derived growth factor
153 (PDGF), integrin/integrin-linked kinase (ILK), notch,
154 fibroblast growth factor (FGF) and Wnt/b-catenin signaling
155 pathways [15–18]. Most of these signals exert their action
156 on E-cadherin repression through the modulation of a set of
157 pleiotropically acting transcription factors, including
158 members of Snail (Snail and Slug) and basic helix-loop-
159 helix (E47 and Twist) families, as well as two double zinc
160 finger and homeodomain (Zeb1 and Zeb2) factors [9].
161 These repressors are expressed in various combinations in a
162 number of malignant tumor types and have been shown in
163 experimental models of carcinoma formation to be causally
164 important for programming invasion [10, 19]. Hence, these
165 repressors are recognized as key inducers of EMT.
166 EMT in EC invasion
167 In EC, hallmarks of EMT have been reported either at
168 the level of E-cadherin loss or at the induction of its
169repressors. On one side, Hurt et al. [20] and Singh et al.
170[21] have described high levels of Zeb1 in relation to
171gynecologic carcinoma progression, and Kyo et al. [22]
172have observed a pattern of twist expression preferentially
173at the ‘marginal regions’ of ECs, which was inversely
174correlated with E-cadherin expression. Snail was also
175proposed to play a role in EC progression and was
176correlated with reduced estrogen-receptor a expression
177[23]. On the other side, several reports [24, 25] have
178associated negative E-cadherin expression, increased
179nuclear b-catenin, and loss of a-catenin with the acqui-
180sition of aggressive biological behavior, especially in
181high-grade tumors. Furthermore, some studies have
182demonstrated a correlation between reduced E-cadherin
183and the presence of lymph node metastasis and/or
184adverse patient outcomes [26–30].
185Independently of the most common features of EMT
186described above, other molecular alterations have been
187consistent with this phenotype. For example, L1CAM
188expression was inversely correlated to the expression of
189hormone receptors and E-Cadherin and was found to be
190associated with poor prognosis [31]. L1CAM up-regula-
191tion was mimicked in EC cell lines treated with the EMT
192inducer TGFb1 and blocked when Slug was depleted. In
193line with this result, L1CAM presents two functionally
194active promoter sites containing b-catenin/TCF-LEF and
195E-boxes, respectively, indicating that its expression can be
196regulated by TGFb1, but also by Wnt/b-catenin [32].
197Conversely, the over-expression of a self-renewal gene,
198called BMI-1, has been found in multiple human cancers,
199including gastric cancer [33], lung cancer [34], breast
200cancer [35], prostate cancer [36], ovarian cancer [37], and
201EC [38]. BMI-1 up-regulation has been found to con-
202tribute to the EMT-derived invasive phenotype in EC
203cells, and its silencing reverts EMT and reduces EC cell
204invasion [39].
205Interestingly, Stewart and Little [40] were the first to
206approach an immunohistochemical identification of the
207distinctive morphological alterations consistent with EMT
208features in EC. They managed to characterize the presence
209of microcystic, elongated and fragmented glands within EC
210tissues, which they named ‘‘MELFs’’. MELFs are specific
211tumor alterations, which, through immunohistochemical
212study, can be identified by strong CK7 expression, showing
213a reduction of E-Cadherin and hormone receptor and
214increased snail expression. Loss of hormone receptors and
215decreased E-cadherin immunoreactivity have been reported
216previously in EC [23, 41–44] and in breast carcinoma
217[45, 46]. Although EMT has been broadly described in EC,
218the molecular pathways responsible for triggering this
219process are still poorly delineated for this type of cancer.
220Here, we will review current literature pertaining to the
221main effectors of EMT in EC.
Fig. 1 General features of epithelial to mesenchymal transition
(EMT). Schematic diagram of the main molecular, morphological
and phenotypical changes occurring in EMT
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223 Presence of progesterone receptors (PR) has been described
224 as an important asset in the prognosis and treatment of EC
225 [47, 48]. In well-differentiated EC, PR expression is usu-
226 ally maintained and treatment with medroxyprogesterone
227 acetate (MPA) is usually successful. In contrast, a loss of
228 PR expression is a negative prognostic factor and is asso-
229 ciated with the development of a more invasive phenotype,
230 in which MPA treatment is only occasionally successful in
231 15–20 % of the cases [43, 49].
232 Recently, Van der Host et al. [44] have postulated that a
233 loss of progesterone signaling in progressive disease may
234 play a role in the induction of EMT, as well as diminished
235 T-cell infiltration. In that study, PR modulated cell lines in
236 the presence of MPA resulted in an inhibition of migration
237 and a down-regulation of mesenchymal markers. An
238 assessment of the pathways involved in EMT showed that
239 progesterone modulated cell lines presented a down-regu-
240 lation of EGF, IGF-1, IL-6, integrin/ILK, PDGF, TGFb,
241 VEGF and Wnt/b-catenin signaling. These altered signal-
242 ing pathways were also modulated in a gene expression
243 study comparing progressive and non-progressive EC tis-
244 sue samples. To date, a link between progesterone and the
245 Wnt/b-catenin signaling pathway has been broadly
246 described [41, 43, 50, 51], though links between proges-
247 terone and other altered pathways remain unclear.
248 TGFb
249 TGFb signals are largely known as tumor promoters of
250 cellular responses, such as proliferation, survival, migra-
251 tion and invasion, and are related to EMT induction in
252 other types of cancer [52]. TGFb exerts its effect by
253 binding to a heteromeric complex of transmembrane ser-
254 ine/threonine kinase, the type I (RI) and type II (RII)
255 receptors. Following ligand binding to the receptors com-
256 plex, RI phosphorylates Smad2 and Smad3. The phos-
257 phorylated Smads form a heteromeric complex with Smad4
258 and translocate into the nucleus to regulate TGFb-respon-
259 sive gene transcription [53].
260 As relates to EC, the disruption of TGFb signaling has
261 been observed at the early stages of carcinogenesis, leading
262 the endometrium to divert from normal growth control
263 [54]. In contrast, increased levels of RII and Smad4 were
264 described in infiltrating E s, when compared to non-infil-
265 trating tissues at the protein level, while Smad2 and Smad4
266 mRNAs were down-regulated. A comparison between the
267 molecular profiles of high risk and low risk of recurrence
268 phenotypes for EC also pointed to a prominent role for
269 TGFb signaling in the acquisition of an aggressive phe-
270 notype [55]. In vitro studies confirmed that TGFb plays a
271principal role at the initiation of EC invasion, through
272promotion of the EMT that leads to the acquisition of an
273invasive phenotype in Hec1a and RL95-2 cells [55, 56].
274ETV5
275ETV5 belongs to the PEA3 subfamily of Ets transcription
276factors, characterized by a sequence of 85 amino acids in
277an evolutionarily conserved DNA-binding domain that
278regulates the expression of a variety of genes by binding to
279a central A/GGAA/T core motif, in cooperation with other
280transcriptional factors and cofactors [57, 58]. Up-regulation
281of the ETV5 gene in EEC was described by Planagumà
282et al. [59] with a specific and significant increase restricted
283to those tumor stages associated with myometrial infiltra-
284tion. Recently, ETV5 has arisen as an inducer of EMT in
285EC through a main regulatory effect on the Zeb1 promoter,
286and has also been found to induce EMT in ovarian cancer
287cell lines [60]. Along with ETV5 over-expression in EC
288cell lines, the main features of EMT were also observed.
289These included a modulation of cell adhesion, cell–cell
290contact and cellular junctions, and actin cytoskeleton
291reorganization. At the same time, main cellular functions
292were altered, as well as cell-to-cell signaling and interac-
293tion and cellular movement, as the principal modified
294biological processes [61].
295Concomitant with EMT, the up-regulation of ETV5 in
296EC also regulated the MMP2 [62] and HEP27 [63] pro-
297moter regions. The former protein is a matrix metallopro-
298teinase, which is primarily responsible for the degradation
299of the helical domains of type IV collagen, i.e., the prin-
300cipal collagen of basement membranes that allows tumor
301cells to infiltrate surrounding tissues. The latter is a
302member of the superfamily of short-chain dehydrogenases/
303reductases that protect tumor cells against apoptosis, which
304is induced by oxidative stress generated during the invasive
305process.
306In our work, we have also identified a number of pro-
307teins involved in the acquisition of invasive capabilities by
308ECs [64], such as lipoma-preferred partner (LPP), which
309acts as a novel co-regulatory partner of ETV5 in the tran-
310scriptional regulation of the EMT process. LPP is reorga-
311nized from cell–cell contacts to focal adhesions when EMT
312is induced by ETV5, and it translocates to the nucleus
313ahead of external stimuli, establishing cross-talk between
314the tumor cells and their surrounding microenvironments
315[61].
316Interestingly, our group linked TGFb and progesterone
317receptor pathways with ETV5 by means of a proteomic
318analysis that compared EC cells stably over-expressing
319ETV5 with both control, non-transfected cells and cells that
320had been transfected with the empty vector [63] (Fig. 2).
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322 Several reports have shown the importance of certain mi-
323 croRNAs in modulating EMT. These microRNAs represent
324 a class of small, non-coding RNAs with important regu-
325 latory functions in diverse biological processes [65, 66],
326 including cancer [67]. In EC, and specifically in the car-
327 cinosarcoma histology from type II EC, Castilla et al. [68]
328 managed to identify specific microRNA signatures that
329 distinguished epithelial from mesenchymal areas. Among
330 the 377 microRNAs assayed, 14 microRNAs were found
331 differentially expressed. The most strongly up-regulated
332 microRNA was miR-155, indicating that this miRNA
333 participated in EMT. The role of this microRNA in EMT
334 had been previously suggested in vitro, in relation to
335 TGFb. TGFb-treated normal murine mammary gland epi-
336 thelial cells underwent EMT, and miR-155 was found to be
337 significantly up-regulated. The ectopic expression of miR-
338 155 also disrupted tight junction formation and promoted
339 cell migration and invasion [69]. Another key finding of
340 this study in carcinosarcomas was the marked down-reg-
341 ulation of all five members of the miR-200 family in the
342 mesenchymal cells. Several studies have demonstrated the
343 miR-200 family to be a powerful marker and determining
344 factor of the epithelial phenotype of cancer cells. In EC cell
345 lines, a member of this family, miR-200c, has been con-
346 firmed to maintain the epithelial phenotype by targeting
347 Zeb1 and Zeb2 and, moreover, to actively repress a pro-
348 gram of mesenchymal and neuronal genes involved in cell
349motility and anoikis resistance [70, 71]. Regarding mi-
350croRNAs regulation in other types of EC, Dong et al. [39]
351unveiled that miR-194 inhibited the EMT of EC cells by
352targeting the oncogene BMI-1.
353Only seven of more than 24,000 entries for ‘‘endometrial
354cancer’’ in PUBMED correspond to ‘‘endometrial cancer’’
355and ‘‘EMT.’’ This data underscores the necessity of more
356research on this topic. It is crucial for us to understand the
357molecular mechanisms of myometrial invasion, as it repre-
358sents one of the most important prognostic variables of EC.
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368dació Santiago Dexeus Font for Clinical Investigation Projects 2009,
369the National Programme of Biotechnology (FIT-010000-2007-26),
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